STOCK TITAN

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SEATTLE, May 27, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will participate in the following investor virtual conferences.

  • Jefferies Virtual Healthcare Conference
    Presentation on Thursday, June 4th at 10 a.m. Pacific Time / 1 p.m. Eastern Time

  • William Blair Virtual Growth Stock Conference
    Fireside Chat on Thursday, June 11th at 10 a.m. Pacific Time / 1 p.m. Eastern Time

  • Goldman Sachs Virtual Healthcare Conference
    Fireside Chat on Thursday, June 11th at 12 p.m. Pacific Time / 3 p.m. Eastern Time

Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech

Investor Contact:
Karina Calzadilla, Vice President, Investor Relations
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

Media Contact:
Beth Keshishian
media@adaptivebiotech.com


Adaptive Biotechnologies Corporation

NASDAQ:ADPT

ADPT Rankings

ADPT Latest News

ADPT Stock Data

532.00M
96.82M
2.83%
97.6%
6.27%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SEATTLE

About ADPT

we are a commercial-stage, biotechnology organization located in the hot biotech locations of seattle, washington and south san francisco, ca. our world class scientists have invented a patent-pending technology that combines advances in high-throughput sequencing with state-of-the-art computer infrastructure to provide an in-depth analysis of the t- and b-cell repertoire, a specific and important part of the immune system. this information is driving the r&d community to support the fights against cancer, auto-immune disease, and much, much more. we're often asked to describe our company culture. it is very easy ... we're a hard working group of top-notch individuals who are passionate about wanting to make a difference in the world. we know our employees are our most valuable asset, and every employee’s contribution is appreciated. open communication and collaboration are always encouraged in every interaction throughout the organization. we have high expectations of ourselves, and